|Bid||123.08 x 1000|
|Ask||123.88 x 800|
|Day's range||121.60 - 124.62|
|52-week range||105.36 - 142.60|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||30.59|
|Earnings date||26 Jan 2022|
|Forward dividend & yield||1.88 (1.49%)|
|Ex-dividend date||13 Jan 2022|
|1y target est||145.18|
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Abbott is a major pharmaceutical company best known for its medical devices, diagnostics, and pediatric and adult nutritional products -- think Pedialyte or Similac. This year, it's being crowned as a dividend king -- meaning the company has increased its annual dividend for 50 consecutive years. Excluding COVID-testing-related sales, Abbott still boasts a nearly 12% increase over pre-pandemic 2019 sales for the quarter.
When it comes to underrated healthcare stocks that smart investors love, Abbott Laboratories (NYSE: ABT) takes the cake. On the contrary, it's exactly Abbott's willingness to compete in these spaces that makes the company one of the sturdiest. Given that Abbott has a market cap of about $238 billion and trailing revenue of $42.3 billion, it shouldn't surprise anyone that the business sometimes struggles to grow as aggressively as a smaller competitor might.